Terns Pharma Q3 net loss $16.8M; cash $187M; pipeline on track for 2023 trials

Terns Pharmaceuticals, Inc.

2022-Q3 EPS reported -$1.50

Net loss of $16.8M for Q3 2022 ($0.44 per share), compared to $11.8M ($0.47) in Q3 2021.
Cash, cash equivalents and marketable securities totaled $187.3M at Sept 30, 2022, providing runway into 2025.
R&D expenses rose to $12.2M (Q3 2022) from $7.2M (Q3 2021); G&A expenses were $5.1M vs $4.7M.
Plan to initiate U.S. Phase 1 trial for TERN-701 (allosteric BCR-ABL) in CML in H2 2023; top-line DUET data for TERN-501 expected H2 2023.
IND-enabling activities for TERN-601 (oral GLP-1R) on track; first-in-human obesity trial planned in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Terns Pharmaceuticals, Inc. reported financial results for three and nine months ended September 30, 2022.

Period: three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 9, 2022, Terns Pharmaceuticals, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.